Savolitinib is a MET-TKI approved in China for the treatment of metastatic NSCLC with MET exon 14 skipping changes that progress after platinum-based chemotherapy or cannot tolerate platinum-based chemotherapy, based on the results of a pivotal phase II trial in NSCLC/lung sarcoma-like carcinoma.[11]. This evidence concerns the gene MET and carcinoma.